Drugs / Tesetaxel
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04312282 | Mar → Sep 2020 | cancer | Odonate Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01337310 | Apr 2011 → Jul 2012 | cancer | Genta Incorporated | Unknown | No outcome recorded |
| Phase 1 | NCT01315431 | Mar 2011 → Aug 2012 | cancer | Genta Incorporated | Unknown | No outcome recorded |
| Phase 1 | NCT01170975 | Jun 2010 → Feb 2011 | cancer | Genta Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT00077077 | Feb 2004 → Jan 2006 | cancer of unknown primary site | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01348009 | May 2011 → Oct 2013 | gastric carcinoma | Genta Incorporated | Unknown | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT03952325 | Jul 2019 → Jun 2021 | breast cancer | Odonate Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03858972 | Feb 2019 → Jun 2021 | breast cancer | Odonate Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01609127 | May 2012 → Sep 2013 | female breast carcinoma | Genta Incorporated | Unknown | No outcome recorded |
| Phase 2 | NCT01573468 | Apr 2012 → Jul 2014 | gastric carcinoma | Genta Incorporated | Unknown | No outcome recorded |
| Phase 2 | NCT01296243 | Feb 2011 → Aug 2012 | prostate cancer | Genta Incorporated | Unknown | No outcome recorded |
| Phase 2 | NCT01221870 | Nov 2010 → Oct 2012 | breast neoplasm | Genta Incorporated | Unknown | No outcome recorded |
| Phase 2 | NCT01215877 | Sep 2010 → Sep 2012 | transitional cell carcinoma | Genta Incorporated | Unknown | No outcome recorded |
| Phase 2 | NCT01095120 | Mar 2010 → Sep 2012 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Genta Incorporated | Unknown | No outcome recorded |
| Phase 2 | NCT01064713 | Feb 2010 → Oct 2014 | cancer, melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01092585 | Feb 2010 → Mar 2012 | melanoma | Genta Incorporated | Unknown | No outcome recorded |
| Phase 2 | NCT00080834 | Feb 2004 → Aug 2006 | colorectal cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03326674 | Dec 2017 → Aug 2020 | breast cancer | Odonate Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tesetaxel | “Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.” PMID 21547572 ↗ May 2011 |
| Known as | DJ-927 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00080834 ↗ |
| Action | Inhibit | “tesetaxel, a novel, orally active, semisynthetic microtubule inhibitor of the taxane class” PMID 21547572 ↗ May 2011 |
| Modality | Small molecule | “tesetaxel, an orally bioavailable taxane” NCT01296243 ↗ |
| Route | Oral | “Patients receive oral DJ-927 on day 1.” NCT00080834 ↗ |